A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering the clinic with a trove of company-generated human data already in hand.

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both dry and wet AMD. As highlighted by Huang and ...

Dry age-related macular degeneration (AMD) management is currently based on regular follow-up for early detection of choroidal neovascularization (CNV), addressing the risk factors and prescribing ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...